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Many RhoGTPase activation proteins (RhoGAPs) are
deleted or downregulated in cancers, but the func-
tional consequences are still unclear. Here, we
show that the RhoGAP ArhGAP11A induces cell-
cycle arrest and apoptosis by binding to the tumor
suppressor p53. The RhoGAP domain of ArhGAP11A
binds to the tetramerization domain of p53, but not to
its family members p63 or p73. The interaction stabi-
lizes the tetrameric conformation of p53 and
enhances its DNA-binding activity, thereby inducing
cell-cycle arrest and apoptosis. Upon DNA damage
stress, ArhGAP11A accumulates in the nucleus
and interacts with p53, whereas knockdown of
ArhGAP11A partially blocks p53 transcriptional ac-
tivity. These findings explain why RhoGAPs are
frequently deleted in cancers and suggest that the
RhoGAP family sits at the crossroads between the
cell-migration and proliferation pathways.
INTRODUCTION
Mammals have evolved a sophisticated regulatory network for
controlling the proliferation of cells, and the stepwise accumula-
tion of genemutations and deregulation impairs this network and
eventually leads to cancer (Frank, 2004). Genes that influence
cell proliferation can be classified as growth suppressors and
oncogenes, and the malignant transformation process is often
accompanied with the downregulation of growth suppressors
and upregulation of oncogenes (Silvera et al., 2010). The expres-
sions of an increasing number of genes are being included as
biomarkers to help cancer prognosis and guide personalized
treatment (Nowsheen et al., 2012).
The Ras homology (Rho) GTPase activation proteins (Rho-
GAPs) are emerging as a new class of biomarkers for diverse
cancers (Kandpal, 2006). The Rho subfamily of small GTPases
regulates cytoskeleton and cell adhesion (Etienne-Manneville
and Hall, 2002), and the RhoGAPs inactivate Rho GTPases by
promoting the hydrolysis of GTP that is bound to Rho. The hu-1526 Cell Reports 3, 1526–1538, May 30, 2013 ª2013 The Authorsman genome encodes 73 members of the RhoGAP family, and
the downregulation of many RhoGAPs has been found in
different types of cancers, including DLC-2 (Deleted in Liver
Cancer-2) in hepatocellular carcinomas (Ching et al., 2003),
DLC-1 in lung, breast, prostate, kidney, colon, uterus, ovary,
and stomach cancers (Liao and Lo, 2008), ArhGAP8 in colorectal
and breast cancers (Johnstone et al., 2004), b-chimerin in breast
cancer, STARD13 in breast and hepatocellular cancers,
ArhGAP20 in leukemia (Herold et al., 2011), and PIK3R1 in pros-
tate cancer (Hellwinkel et al., 2008). It has been generally
assumed that the association of RhoGAPs with cancer is medi-
ated by the Rho pathway, because the Rho GTPases are well-
known regulators of cell migration and thereby may influence in-
vasion and metastasis (Ridley, 2004). However, it is not known
whether the association of RhoGAPs with cancer phenotypes
could be mediated by Rho-independent pathways.
In the present study, we demonstrate that several RhoGAPdo-
mains bind to the p53 tumor suppressor protein and promote its
transcriptional functions. We first identified ArhGAP11A as an
important neurite inducer that physically interacts with p53 in
embryonic oligodendrocytes, and further domain truncation ex-
periments revealed that the RhoGAP domain binds to the p53
tetramerization domain (TD). Second, we found that the tetra-
meric conformation of the p53 TD is crucial for the interaction
with RhoGAP, and multiple hydrogen bonds are involved in the
RhoGAP-p53 TD interaction. Upon DNA damage stress,
ArhGAP11A is upregulated and translocated to the nucleus,
where it binds to p53 and induces cell-cycle arrest and
apoptosis. Third, we studied whether different members of the
RhoGAP family could affect p53 function. Through these efforts,
we aim to provide insight into the mechanism by which depletion
of RhoGAPs associate with malignant phenotypes.RESULTS
Identification of ArhGAP11A in Complex with p53
We began by identifying the upregulation of ArhGAP11A in
stressed oligodendrocytes. To mimic the trauma injury on nerve
cells, ultrasound stresswas applied to oligodendrocytes isolated
from 1-week-old mice, which caused morphological disorder
and injury to the neurites (Figure S1A). By using two-dimensional
blue native/SDS-PAGE (2D BN/SDS-PAGE), we found that the
enrichment of a protein complex consisted of proteins with mo-
lecular masses of 110 and 53 kDa (Figures 1A–1C), which were
identified as ArhGAP11A and p53, respectively, by mass spec-
trometry (Figures 1D and 1E). The mRNA levels of p53 and its
downstream genes CDKN1A andMDM2were increased in ultra-
sound-treated cells, suggesting the activation of p53 function
(Figure S1B). The physical interaction between endogenous Arh-
GAP11A and p53 was confirmed by coimmunoprecipitation
(coIP) assay in differentiating mouse oligodendrocyte progenitor
cells (OPCs) (Figure 1F), human neuron HCN-2, mouse neuron
CATH.a, and rat neuroblastoma B35 cells (Figure S1C). The co-
localization of p53 and ArhGAP11A was also detected in both
cytoplasm and nucleus of human glioma U87 cells, and DNA
damage induced by irradiation increased the levels of both pro-
teins in the cell nucleus (Figure 1G). Western blot of nuclear and
cytoplasmic fractions also suggested that irradiation increased
the levels of p53 and ArhGAP11A proteins, especially in the
nucleus (Figure 1H). Without DNA damage stress, ectopic
expression of ArhGAP11A increased the distribution of p53 in
the cytoplasm, as shown by western blot of nuclear and cyto-
plasmic protein extracts (Figure S1D).
When ArhGAP11A was overexpressed in the osteosarcoma
U2OS cells, it induced cell elongation and the formation of neu-
rite-like structures (Figure S1E). Moreover, the knockdown of
ArhGAP11A in differentiating OPCs impaired the formation of
neurite structures, thus suggesting a key role for ArhGAP11A in
the regulation of oligodendrocyte morphology (Figure S1F).
Consistently, we detected the upregulation of ArhGAP11A in
OPCs, and after in vitro differentiation into oligodendrocytes,
the level of ArhGAP11A was decreased (Figures S1G and
S1H). In addition, direct sampling of embryonic mouse brains
also revealed the upregulation of ArhGAP11A mRNA and protein
in embryonic days 9.5 and 11.5, respectively (Figures S1I and
S1J), during which most neural progenitor cells shift from prolif-
eration to neuronal differentiation. The interaction with p53 may
thus be explained by the function of ArhGAP11A in transforming
OPCs from proliferation phase into differentiation phase, which
involves the suppression of cell-cycle progression and regula-
tion of cell morphology.
The RhoGAP Domain of ArhGAP11A Binds to the p53 TD
To identify the domain of ArhGAP11A that interacts with p53, we
initially analyzed the structure of ArhGAP11A protein. According
to the prediction by the SWISS-MODEL database, ArhGAP11A
includes three domains (Figure 2A): a RhoGAP domain near
the N terminus (amino acids 46–246), and two uncharacterized
domains respectively located in the center (387–516) and C ter-
minus (590–997) of the protein.We thus cloned different domains
of ArhGAP11A (amino acids 1–45, 247–516, and 517–1023) into
pcDNA3-Flag vector and coexpressed them with pcDNA3-HA-
p53 in SaOS-2 cells (p53 null). Interestingly, coIP assay revealed
the physical interaction between p53 and the RhoGAP domain,
but not with the other regions of ArhGAP11A (Figure 2B). Consis-
tently, immunofluorescence with antibodies specific for Flag and
HA tags revealed the colocalization of p53 with full-length
ArhGAP11A and its RhoGAP domain (46–246), but not with other
domains (Figures 2C, S2A, and S2B).CThe part of p53 that interacts with ArhGAP11A was further
determined by domain truncation experiments. As indicated in
Figure 2D, the p53 protein includes a transactivation domain
(AD; amino acids 1–44), a proline-rich domain (PRD; 64–92), a
central DNA-binding domain (DBD; 102–292), and a TD (325–
356). By respectively deleting these domains and coexpression
with ArhGAP11A, we found that only the p53 TD is necessary
for the interaction with ArhGAP11A (Figure 2E). Intriguingly, a
tetrameric conformation of the p53 TD is required for the binding
with ArhGAP11A because the dimeric mutation L344A (Mateu
and Fersht, 1998) and monomeric mutation L344P (Davison
et al., 1998) were both able to abolish the interaction with
ArhGAP11A (Figure 2E). The p53 family members p63 and p73
share high homology with p53 in their DBDs, but not in their
TDs; thus, it is of interest to determine if ArhGAP11A can interact
with the TDs of p63 and p73. We coexpressed ArhGAP11A and
p63 or p73 in SaOS-2 cells and examined their interactions by
immunofluorescence and coIP. As expected, coIP demonstrated
no physical interaction between ArhGAP11A and p63/p73 (Fig-
ure 2F), and immunofluorescence showed no colocalization be-
tween ArhGAP11A and p63/p73 in cells (Figures S2C and S2D).
The Mode of RhoGAP-p53 Interaction
To study the precise manner of interaction between ArhGAP11A
and p53, we employed the GRAMM-X protein-protein docking
algorithm (Tovchigrechko and Vakser, 2006) to predict the
bound conformation of the ArhGAP11A RhoGAP domain (Pro-
tein Data Bank [PDB] ID code 3EAP) and p53 TD (PDB ID code
2J0Z). Intriguingly, the RhoGAP domain perfectly matched with
the p53 TD in terms of geometry and electrostatic complementa-
tion (Figures 3A and 3B), but such complementation was not
found for p63 or p73. The binding surface involved the N-terminal
region of the ArhGAP11A RhoGAP domain and each of the four
p53 TD subunits (Figure 3C), thus explaining why a tetrameric
conformation of the p53 TD is crucial for the binding with Rho-
GAP. We also predicted the interaction between p53 and other
RhoGAP domains available from PDB (ArhGAP1, DLC-1/
ArhGAP7, and RICS). Both ArhGAP1 and DLC-1 exhibited a
similar binding mode to p53 as ArhGAP11A, but RICS could
not dock with p53 due to sterical clash of its residues ARG398
and VAL427 (Figure S3A).
We validated the RhoGAP-p53 TD-binding mode by designed
mutations inside or outside the contact surface. Using the FoldX
force field (Guerois et al., 2002), we selected mutations that
could disrupt the intermolecular hydrogen bonds but had little ef-
fect on the folding stability of individual proteins (H64E, S67V,
D71S, T74Y, S75H, and E77I). Three nondestabilizing mutations
outside the predicted binding surface (E150L, D165A, and
K212H) as well as the arginine finger mutation R87A were
included as controls (Figure 3D). The in vitro functional assay
of immunopurified proteins suggested that all of the designed
mutants retained the RhoGAP activity (Figure S3B). By coex-
pressing different ArhGAP11Amutants with p53 and subsequent
coIP assay, we found that the hydrogen-bond-disrupting muta-
tions suppressed the interaction between ArhGAP11A and p53
(Figure 3E). On the contrary, the mutations outside the predicted
binding site did not affect the RhoGAP-p53 interaction (Fig-
ure 3E). These results confirmed the binding surface betweenell Reports 3, 1526–1538, May 30, 2013 ª2013 The Authors 1527
Figure 1. Identification of ArhGAP11A-p53 Interaction
(A) 2D BN-SDS-PAGE of primary oligodendrocytes. The first horizontal dimension separated protein complexes according to their molecular sizes, and
the second vertical dimension displayed each component of the complexes. Red arrow indicates the regions that are enlarged in (C). MW, molecular
weight.
(B) 2D BN-SDS-PAGE of primary neurons treated with ultrasound. Red arrow indicates the regions that are enlarged in (C).
(C) Zoomed display of selected regions in (C) and (D). The silver-stained proteins were identified by mass spectrometry, which indicated ArhGAP11A and p53 in
the same complex.
(D) MALDI-TOF mass spectrometry of in-gel tryptic digest from the 2D BN/SDS-PAGE shown in (E). The lower subpanels describe the mass and
matched sequences. The fragments with masses of 1,578 and 1,796 respectively correspond to p53 sequences CSDGDGLAPPQHLIR and FEMFRELNEALELK.
(E) Mass spectrometry of ArhGAP11A digested by trypsin in gel. The fragments with masses of 1,483, 1,523, and 1,584 matched ArhGAP11A sequences
GPTAPLITSGLEAQK, FVVNNNVAFSPGMK, and TAQASASPLILTPSVK, respectively.
(F) Oligodendrocytes under mechanical stress were immunoprecipitated for ArhGAP11A, and p53 was detected in the precipitated complex. Suppression of
endogenous ArhGAP11A by siRNA inhibited the coIP of p53. IP, immunoprecipitation; WB, western blot.
(legend continued on next page)
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RhoGAP and the p53 TD and suggested a key role of hydrogen
bonds in stabilizing their interaction.
Next, we performed BN-PAGE to examine the effect of Rho-
GAP on p53 oligomerization. The immunopurified p53 protein
(160 ng) was incubated with RhoGAP (0–40 ng), and the protein
complexes were fractionated according to their native molecular
weight by BN-PAGE. After western blot, the Do-1 antibody was
used to label p53 on the blotted membrane. The BN-PAGE re-
vealed that purified p53 protein formed monomers, dimers,
and tetramers in vitro (Figure S3C). As the addition of RhoGAP
increased, the monomeric and dimeric p53 species gradually
decreased, whereas a band that corresponded to RhoGAP-
bound tetramer became abundant (Figure S3C). These results
suggest that RhoGAP promotes the assembly of p53 mono-
mers/dimers into tetramers.
RhoGAP Promotes p53 Function upon DNA Damage
Because p53 is active as a tetramer (Brandt et al., 2009), the
binding to RhoGAP may promote the transcriptional functions
of p53. To test this, we manipulated ArhGAP11A expression
and monitored p53 transactivity using a PG-13 luciferase re-
porter that contains p53-responsive promoter upstream of the
luciferase (el-Deiry et al., 1992). Although ArhGAP11A alone
did not transactivate the PG-13 reporter, it could increase the
transactivity of p53 by approximately 2-fold (Figure S4A). Both
p63 and p73 showed weaker transactivity upon the PG13 re-
porter, which was, however, not affected by the coexpression
of ArhGAP11A (Figure S4A). Consistently, quantitative RT-PCR
(qRT-PCR) assay also revealed the ability of ArhGAP11A to pro-
mote the transactivity of p53 (but not of p63 or p73) on target
genes p21, GADD45A, Cyclin B1, and BAX (Figures S4B–S4E).
These results suggest different regulatory mechanisms for p53,
p63, and p73 in their TDs and may help to explain the partially
overlapping but distinct functions of p53 family members.
To examine the effect of RhoGAP on p53 activation upon DNA
damage stress, we controlled the expression of ArhGAP11A and
analyzed the function of endogenous p53 in irradiated human gli-
oma U87 cells. When the U87 cells were exposed to 10 Gy
ionized irradiation, the p53 downstream genes involved in cell-
cycle arrest (CDKN1A, CCNG1, GML) and apoptosis (BAX,
NOXA, PUMA) were significantly upregulated, suggesting the
activation of p53 function (Figure 4A). Importantly, interfering
ArhGAP11A by specific siRNAs suppressed the expression of
p53 target genes, whereas ectopic expression of ArhGAP11A
promoted p53 function and upregulated CDKN1A, CCNG1,
GML, BAX, NOXA, and PUMA (Figure 4A). In order to test the ef-
fect of ArhGAP11A on p53-dependent cell-cycle arrest and
apoptosis, the irradiated U87 and B35 cells were transfected
by siRNA/cDNA for ArhGAP11A and analyzed by flow cytometry.
As a result, irradiation significantly increased the distribution of(G) Immunofluorescence of p53 and ArhGAP11A in human glioma U87 cells befo
monoclonal antibody in red, and ArhGAP11A was labeled with a rabbit polyclonal
endogenous p53 and ArhGAP11A was performed to test the specificity of antibo
(H) ArhGAP11A and p53 are upregulated and accumulated in cell nucleus upon DN
before and after irradiation of U87 cells. The levels of endogenous p53 and ArhG
western blot. The lamin A/C protein was included as a marker for nuclear fractio
extraction.
See also Figure S1 for details.
Ccells in subG1 and G1 phases, and knockdown of ArhGAP11A
suppressed the effects of irradiation on cell-cycle progression
(Figures 4B and 4C). Consistently, BrdU incorporation assay re-
vealed a strong inhibitory effect of irradiation on the proliferation
of U87 and B35 cells, and knockdown of ArhGAP11A by siRNA
partially restored cell proliferation. (Figures 4D and 4E). These re-
sults together suggested that ArhGAP11A modulates p53 func-
tion in response to irradiation-induced DNA damage.
We then applied quantitative chromatin immunoprecipitation
(ChIP) assay to determine whether ArhGAP11A could modulate
the binding of p53 to target promoters in vivo. The human glioma
U87 cells that bear wild-type p53 (Kondo et al., 1995) were irra-
diated and transfected with siRNAs specific for ArhGAP11A, fol-
lowed by ChIP using antibodies for p53 or for ArhGAP11A. The
DNA recovered by ChIP was specifically amplified for the pro-
moter regions of target genes CDKN1A, CCGN1, GML,
GADD45A, BAX, NOXA, and PUMA using quantitative PCR. As
a result, exposure to irradiation significantly increased the bind-
ing of p53 to the promoters of the aforementioned genes,
whereas the knockdown of ArhGAP11A by siRNAs decreased
the binding of p53 to target promoters (Figure 4F). Moreover,
irradiation also induced the binding of ArhGAP11A to the pro-
moter of CDKN1A, which was dependent on p53 (Figure 4G).
To determine if the effect of ArhGAP11A on p53 function is
dependent on the Rho GTPase pathway, we tested the
ArhGAP11A mutants that do not bind to p53 but retained Rho-
GAP activity (T74Y, E77I, K212H). The luciferase reporter assay
revealed that none of the aforementioned mutants could affect
the transactivity of p53 (Figure S4F), but the R87A mutant that
was devoid of GAP activity could still promote p53 function (Fig-
ure S4G). These results suggested an important role of RhoGAP-
p53 interaction but not the GAP function in regulating p53 func-
tion.Moreover, depletion of ArhGAP11A by siRNAs did not affect
mRNA and protein levels of p53 (Figures S4H and S4I). We per-
formed in vitro RhoGAP assays to determine the specificity of
ArhGAP11A upon the Rho GTPases RhoA, Rac1, and Cdc42
and found that ArhGAP11A significantly increased the intrinsic
GTPase activity of RhoA, but not of Rac1 andCdc42 (Figure S4J).
Consistently, overexpression of ArhGAP11A also decreased the
level of active RhoA in U87 cells, as revealed by GST-RBD pull-
down assay (Figure S4K). Moreover, the addition of purified p53
protein into the RhoGAP assay enhanced the GTPase-activating
function of ArhGAP11A (Figure S4L), which suggested that the
interaction between ArhGAP11A and p53 could modulate the
functions of both proteins.
ArhGAP1 and ArhGAP15 Bind to p53 and Are
Suppressed in Cancers
The ability of the RhoGAP domain to interact with p53 protein led
to the question whether other RhoGAP family members can alsore and after irradiation. The endogenous p53 protein was stained with a mouse
antibody in green. The cell nucleus was stained by DAPI in blue. Knockdown of
dy labeling.
A damage stress. Proteins in cytoplasmic and nuclear fractions were extracted
AP11A in whole-cell, cytoplasmic, and nuclear fractions were determined by
n, and b-tubulin was detected to control the efficiency of cytoplasmic protein
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Figure 2. The RhoGAP Domain Binds to the p53 TD
(A) Domain annotation of ArhGAP11A protein according to the SWISS-MODEL database. Three globular domains were predicted, including amino acids 46–246
(RhoGAP), 387–516, and 590–997.
(B) The physical interaction between HA-p53 and Flag-ArhGAP11A was determined by coIP assay. Specific antibody for Flag tag was used to pull down
ArhGAP11A or its mutants, and the interacting p53 was detected with antibody for HA tag. The detection with Flag antibody suggested similar levels of
ArhGAP11A immunoprecipitated in all conditions. The input amounts of p53 and ArhGAP11A are also shown.
(C) Colocalization of p53 with ArhGAP11A and its GAP domain. Different domains of ArhGAP11A were cloned into pcDNA3-Flag vector and coexpressed with
pcDNA3-HA-p53 in SaOS-2 cells. Immunofluorescence using specific antibodies for Flag and HA tags was applied to determine the localization of ArhGAP11A
(legend continued on next page)
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bind to p53. According to the target specificity, RhoGAPs mainly
include RhoA-GAPs, Cdc42-GAPs, and Rac-GAPs. Given that
ArhGAP11A is a RhoA-GAP, we further tested a Cdc42-GAP
ArhGAP1 (Nassar et al., 1998) and a Rac-GAP ArhGAP15
(Seoh et al., 2003) on their abilities to interact with p53. A Ras-
specific GTPase-activating protein RASA1 (Boon et al., 2005)
was also included in the assay. Interestingly, p53 physically in-
teracted with ArhGAP1 and ArhGAP15, but not with RASA1 (Fig-
ure S5A). Consistently, both ArhGAP1 and ArhGAP15 colocal-
ized with p53 when coexpressed in cells, but no colocalization
was observed for RASA1 (Figures S5B and S5C). When DNA
damage was induced in the human colorectal cancer (CRC)
HCT-116 cells by treatment with 100 mg/ml etoposide, the
endogenous p53 and ArhGAP15 proteins were upregulated
and colocalized in the cell nucleus, suggesting the interaction
of both proteins (Figure 5A). In the luciferase reporter assay,
ArhGAP1 and ArhGAP15 significantly increased the transcrip-
tional function of p53, but the coexpression with RASA1 did not
affect p53 activity (Figure 5B). These results suggest that the abil-
ity to interactwithp53 is specific forRhoGAP,but not forRasGAP.
The pro-p53 function of ArhGAP1 and ArhGAP15 indicates
that these proteins may be downregulated in the process of tu-
mor formation. Indeed, reanalysis of published microarray data
(GEO data set GDS2545 with 171 samples) suggested that
ArhGAP1 is progressively decreased in primary prostate cancer
(p < 0.01) and in metastatic prostate cancer (p < 1 3 107; Fig-
ure S5D). In CRCs, we analyzed 98 patient tissue samples by
immunofluorescence and immunohistochemistry (sample
description and statistics in Tables S1 and S2) and found that
the level of ArhGAP15 protein was significantly decreased in
CRCs as compared to normal tissues (p < 0.0001, Wilcoxon
signed rank test; Figures 5C, 5D, and S5E). In addition, qRT-
PCR analysis of 36 normal and CRC tissues suggested that the
mRNA level of ArhGAP15 is also lower in CRC tissues than in
normal epithelium (p < 0.001, t test; Figure 5E). According to
the Catalogue of Somatic Mutations In Cancer (COSMIC) data-
base (Forbes et al., 2011), ArhGAP15 mutations were identified
in 3 of 15 sequenced CRC samples. These findings consistently
suggest that the loss of ArhGAP15 function may be associated
with the occurrence of CRC.
Specificity of RhoGAP-p53 Interaction
Given that at least three RhoGAP domains share the ability of
regulating p53 function, it is meaningful to test a broader range
of RhoGAPs for the effect on p53 transactivity. To this end, we
performed luciferase reporter assay in SaOS-2 cells that were
cotransfected with p53 and different RhoGAPs. The 26 tested
RhoGAPs, as listed in Table S3, represent one-third of all known(green) and p53 (red). The Pearson’s correlation coefficient (R) between the inten
zation. Although thewild-type p53 colocalizedwith full-length ArhGAP11A or its Rh
in Figure S3A) did not show colocalization.
(D) The p53 protein contains AD, PRD, DBD, and TD. WT, wild-type.
(E) CoIP assay revealed that deletion of the TD or interfering its conformation with
between ArhGAP11A and p53. SaOS-2 cells were cotransfected with Flag-tagge
D357–393, L344P, and L344A).
(F) CoIP suggested that ArhGAP11A physically interacted with p53 but not p63/p
tagged ArhGAP11A is shown in the middle panel. The input control of HA-tagge
See also Figure S2 for details and statistical analyses.
CRhoGAPs. Interestingly, 15 out of the 26 RhoGAPs showed the
ability to increase p53 transactivity (Figure S6A), among which
ArhGAP11A, ArhGAP23, and TAGAP showed stronger effects.
Nevertheless, the functional readout under forced overex-
pression only represents the potential ability of RhoGAPs to
regulate p53, but their actual effects on p53 in specific cell
type should also be affected by their endogenous expression
level and subcellular localization. In fact, when cells were not
stressed by DNA damage, respectively knocking down one of
these RhoGAPs did not yield a profound effect on p53 trans-
activity (Figure S6B). However, irradiation-induced DNA
damage seemed to ‘‘switch on’’ certain RhoGAPs (especially
for ArhGAP11A) in U87 cells, resulting in upregulation and nu-
clear translocation of the protein (Figure 6A, and also previously
shown in Figure 1H). Under such a condition, knocking down
ArhGAP11A significantly reduced p53 transactivity. In addition,
minor effects were also observed for ArhGAP15 and TAGAP
(Figure 6B), which possess p53-regulating ability but were not
upregulated by DNA damage. Collectively, our findings indicate
that RhoGAPs’ effects on p53 are determined by multiple fac-
tors, including their intrinsic binding potency, the expression
level, and subcellular localization in response to genotoxic
stresses in a given cell type.
DISCUSSION
As the involvement of RhoGAPs in cancer phenotypes becomes
increasingly evident, most studies have been exploring this link
through the Rho signaling pathway (Kandpal, 2006). We report
here a Rho-independent mechanism by which some RhoGAPs
directly bind to p53 and promote its transcriptional functions.
The RhoGAP-p53 interaction is physiologically relevant to the
p53-dependent responses to DNA damage, and the expression
level of ArhGAP11A affects cell proliferation and apoptosis. The
ability to interact with p53 is shared by multiple RhoGAPs, but
not by the Ras-GAP, which exhibits limited structure similarity
with RhoGAPs (Jiang and Ramachandran, 2006). The other
members of the p53 family (p63 and p73) do not interact with
RhoGAPs, which helps to explain the partial overlap but distinct
functions of p53 family members. Because p53 plays central
roles in the maintenance of genome fidelity by regulating cell-
cycle arrest and apoptosis (Berns, 2010), it is thus not surprising
that RhoGAPs are frequently deleted or suppressed in cancers.
In this study, we have reported the significant downregulation of
ArhGAP15 and ArhGAP1 in colorectal and prostate cancers.
Combining the finding that ArhGAP15 and ArhGAP1 can pro-
mote the transcription function of p53, it is likely that both genes
function as tumor suppressors.sity profiles of ArhGAP11A and p53 was calculated to indicate their colocali-
oGAPdomain (46–246), other domains (1–45, 247–516, and 517–1,023, shown
L344P (monomeric) or L344A (dimeric) mutations could abolish the interaction
d ArhGAP11A and HA-tagged p53 or its variants (DAD, DPRD, DDBD, or DTD,
73 when coexpressed in SaOS-2 cells (upper panel). The input amount of Flag-
d p53/p63/p73 is presented in the lower panel.
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Figure 3. Binding Mode between the RhoGAP Domain and p53 TD
(A andB) The bindingmode of the ArhGAP11ARhoGAP domain and p53 TD as predicted by theGRAMM-X algorithm. The RhoGAP domain is displayed in yellow,
and the four chains of the p53 TD tetramer are respectively shown in red, orange, blue, and green. The conformation of Rho GTPase (cyan) bound to RhoGAP
(yellow) was superposed from the RhoA-RhoGAP complex structure determined by X-ray diffraction (PDB 1OW3). (A) and (B), respectively, show the side view
and top view of the complex.
(C) The protein complex of Rho GTPase, RhoGAP, and p53 TD displayed in ribbon mode from the same angle view as in (A). The different protein chains are
labeled with the same color scheme as in (A) and (B). The residues of RhoGAP that formed hydrogen bonds with the p53 TD are marked in purple (H64, S67, D71,
T74, S75, and E77).
(D) The effect of designed mutations on the interacting energy of the protein complex and folding stability of individual proteins as predicted by the FoldX force
field (Guerois et al., 2002). The mutations H64E, S67V, D71S, T74Y, S75H, and E77I are predicted to destabilize the protein complex without affecting the proper
folding of individual proteins, whereas the mutations outside the binding surface (E150L, D165A, and K212H) were predicted to have no effect on complex
formation.
(E) CoIP assay of HA-tagged p53 and Flag-taggedwild-type/mutant ArhGAP11A coexpressed in SaOS-2 cells. TheHA-tagged p53was immunoprecipitated, and
the interacting ArhGAP11A was detected by western blot using specific antibody for Flag tag (upper panel). The input controls of ArhGAP11A and p53 are shown
in middle and lower panels, respectively. Both hydrogen bond-disrupting mutants (H64E, S67V, D71S, T74Y, S75H, and E77I) and control mutants outside the
binding surface (E150L, D165A, and K212H) were included in the assay.
See also Figure S3 for details.Our study also adds to the complexity of p53 functional regu-
lation in its C terminus. Current knowledge about the posttrans-
lational modifications in p53 C terminus includes phosphoryla-
tion (MacLaine and Hupp, 2011), acetylation (Brooks and Gu,1532 Cell Reports 3, 1526–1538, May 30, 2013 ª2013 The Authors2011), and ubiquitination (Rodriguez et al., 2000), and these
modifications affect p53 function by stabilizing the protein or
translocating it to the nucleus. Moreover, the p53 function can
also be regulated by the binding of Ref-1 (Hanson et al., 2005),
(legend on next page)
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14-3-3 (Rajagopalan et al., 2008), and c-Abl (Nie et al., 2000) to
its C terminus, but the precise mode of their interactions is still
missing. Our data reveal that RhoGAPs bind to the TD of p53
and that the experimentally validated docking model provides
structural information for their interaction. The binding to the
RhoGAP domain requires the assembly of the p53 TD into a ho-
motetramer, which is consistent with the quaternary structure of
p53 resolved with electron microscopy by Tidow et al. (2007) but
does not support the model presented by Aramayo et al. (2011),
in which the N and C terminals first contact to assemble the p53
tetramer.
The results in the present study indicate the dual roles of Rho-
GAPs in regulating the p53 and Rho signaling pathway. The p53
protein is in equilibrium between monomeric, dimeric and tetra-
meric conformations (schematic representation in Figure 7), and
the tetrameric p53 binds to promoters with a significantly higher
affinity (Brandt et al., 2009). The RhoGAP domain interacts with
the p53 TD and stabilizes its tetrameric conformation (Figure 7A).
This promotes the transcriptional function of p53 upon down-
stream target genes that are involved in cell-cycle arrest and
apoptosis (Figure 7B). RhoGAPs regulate actin remodeling and
cell morphology through the Rho GTPase pathway (Figure 7C),
and by enhancing p53 function, RhoGAPs also regulate cell prolif-
eration. These twopathwayssynergeticallymediate the regulatory
effectsofRhoGAPsondifferentiation andproliferation (Figure 7D).
Given the fact that the RhoGAP family includes 73 members
that are involved in various biological processes, the findings
of this study may have broader implications. Currently, most
RhoGAPs have not been characterized for their relationship
with cancers, and thus a thorough scan is needed to determine
the mutations and expression levels of RhoGAPs in different
types of cancers. These efforts would benefit the evaluation of
RhoGAPs as potential biomarkers and therapeutic targets for
cancer treatment.
EXPERIMENTAL PROCEDURES
Protein-Protein Docking and Stability Analysis
The binding surface of the ArhGAP11A RhoGAP domain (crystal structure,
PDB ID code 3EAP) and p53 TD (PDB ID code 2J0Z) was predicted by the
GRAMM-X server following the application instructions by TovchigrechkoFigure 4. ArhGAP11A Promotes p53 Function and Induces Cell-Cycle
(A) qRT-PCR assay of p53 downstream genes in irradiated human glioma U8
ArhGAP11Awas performed using two distinct siRNAs (#1 and #2), andmRNA leve
PCR and normalized using ACTB. Data represent mean values ± SD of four inde
(B and C) Percentage of cells in different cell-cycle phases after treatment by irr
roblastoma B35 cells were respectively treated by irradiation and transfection of
cell distribution in sub-G1, G1, S, and G2/M phases. Data represent mean values ±
(D and E) BrdU incorporation of U87 and B35 cells treated by irradiation and siRN
percentage of cells that were positively stained by a specific antibody for BrdU wa
SD of four independent experiments (**p < 0.01, ***p < 0.001, Student’s t test).
(F) The U87 cells were irradiated and transfected with siRNAs (#1 and #2) specific
DNA recovered by ChIP was specifically amplified for the promoter regions of C
PCR. The exon 1 of GAPDH and a site away from the promoter of CDKN1A wer
experiments (***p < 0.001, **p < 0.01, *p < 0.05, Student’s t test).
(G) U87 cells were irradiated, transfected with siRNA for ArhGAP11A or p53, a
promoter of CDKN1A could be amplified from the recovered DNA, but the knockd
ArhGAP11A. Data represent mean values ± SD of four independent experiments
specificity of antibody for ArhGAP11A.
See also Figure S4 for details.
1534 Cell Reports 3, 1526–1538, May 30, 2013 ª2013 The Authorsand Vakser (2006). Briefly, the RhoGAP domain and p53 TD were respectively
defined as receptor and ligand proteins, and no amino acid was predefined as
interface residue or paired interacting residue. The docking model with highest
stability was selected for further experimental validation. The effects of muta-
tions on the individual conformational stability and binding energy of the
ArhGAP11A RhoGAP domain and p53 TD were estimated using the FoldX
force field (Fernandez-Escamilla et al., 2004). All parameters were set
to default: temperature, 298 K (pH 7); gas constant, 19,859 3 103 kcal 3
mol1 3 K1; ion strength, 0.05 M).
Construction of Expression Vectors and Mutagenesis
The pcDNA3-HA-p53, pcDNA3-HA-p63, and pcDNA3-HA-p73 were con-
structed by inserting PCR-amplified cDNA sequences into pcDNA3 vector
(Invitrogen). The expression vectors pCMV6-Flag-ArhGAP11A, pCMV6-Flag-
ArhGAP1, and pCMV6-Flag-ArhGAP15 and other RhoGAPs are commercially
available (OriGene). All deletion and point mutations were generated by oligo-
nucleotide primer-based PCR mutagenesis using Pwo DNA polymerase
(Roche). The transcriptional activity of p53 was examined by PG13-luciferase
reporter plasmid that contains 13 contiguous p53 DNA-binding sites upstream
of the firefly luciferase gene, which has been described elsewhere (el-Deiry
et al. 1992). The pRL-CMV vector (Promega), carrying a Renilla luciferase,
was used as a control vector.
Primary Culture of OPCs from Mice
For details, see the Extended Experimental Procedures.
Transfection of Plasmids and siRNAs
The scrambled siRNA with sequence 50-UAAGGCUAUGAAGAGAUAC-30 has
been described previously by Yan et al. (2007a), and the specific siRNA that tar-
getsp53 (sequence50-CAGTCTACCTCCCGCCATA-30) hasalsobeenvalidated
in different studies (Masse et al., 2012; Yan et al., 2007b). The specific siRNAs
against different RhoGAPs have been listed in Table S3. Transfection of expres-
sion vectors or siRNAswas performed using FuGENEHD (Promega) according
to the product manual. For details, see the Extended Experimental Procedures.
Tissue and Cell Immunofluorescence
Immunofluorescence assay was performed as described previously (Cottle
et al., 2013). This study was approved by the ethical review board at Shanghai
Jiao Tong University School of Medicine, and all patients participating in this
study gave informed consent prior to surgery. For details, see the Extended
Experimental Procedures.
2D BN/SDS-PAGE and Mass Spectrometry
Cells were rinsed with ice-cold 20 mM Tris-HCl, 150 mM NaCl (pH 7.4) (TBS),
and lysed with 18 mM 3-((3-cholamidopropyl)dimethylammonio)-1-propane-
sulfonic acid (CHAPS) in TBS with DNase and protease inhibitors for 30 minArrest and Apoptosis
7 cells transfected by siRNA or cDNA for ArhGAP11A. The knockdown of
ls of CDKN1A, CCNG1, GML, BAX, NOXA, and PUMAwere quantified by qRT-
pendent experiments (*p < 0.05, **p < 0.01, ***p < 0.001, Student’s t test).
adiation and knockdown of ArhGAP11A. The human glioma U87 and rat neu-
siRNA specific for ArhGAP11A, followed by flow cytometry characterization of
SD of four independent experiments (**p < 0.01, ***p < 0.001, Student’s t test).
A transfection. Cells were incubated in the presence of BrdU for 6 hr, and the
s counted to indicate their DNA synthesis rates. Data represent mean values ±
for ArhGAP11A or p53, followed by ChIP using the Do-1 antibody for p53. The
DKN1A, CCGN1, GML, GADD45A, BAX, NOXA, and PUMA using quantitative
e included as controls. Data represent mean values ± SD of four independent
nd immunoprecipitated using antibody for ArhGAP11A. After irradiation, the
own of p53 using siRNA disrupted the binding between CDKN1A promoter and
. Amplification of the exon 1 of GAPDH showed no product, suggesting good
Figure 5. ArhGAP1 and ArhGAP15 Promote p53 Transactivity and Are Suppressed in Cancers
(A) p53 and ArhGAP15 colocalized in etoposide-treated CRC cells. The human CRCHCT-116 cells were added with 100 mg/ml etoposide and incubated for 24 hr,
followed by immunostaining with antibodies for p53 and ArhGAP15. Nucleus was stained with DAPI in blue.
(B) Luciferase reporter assay of SaOS-2 cells coexpressing p53 and ArhGAP1/ArhGAP15/RASA1. The SaOS-2 cells were cotransfected with p53, luciferase
reporter and ArhGAP1, ArhGAP15, or RASA1 plasmids. The resultant luciferase activity was measured and normalized to indicate p53 transcriptional activity.
Data represent mean values ± SD of four independent experiments. Both RhoGAPs (ArhGAP1 and ArhGAP15) promoted p53 transactivity upon the PG-13
reporter (Student’s t test), but the RasGAP RASA1 did not affect p53 function.
(C) Immunofluorescence (IF) and immunohistochemistry (IHC) staining of ArhGAP15 protein in human CRC tissues. For IF assay, the tissue sections were labeled
with specific antibody for ArhGAP15 in green, and cell nucleus was stained by DAPI in blue (left panels). In IHC assay, the ArhGAP1 protein was stained in brown,
and cell nucleus was stained in dark purple. The tumor regions are surrounded by dashed lines and marked with a ‘‘T.’’
(D) Statistical analysis of ArhGAP15 protein expression in normal and cancerous colorectal tissues. The intensity of ArhGAP15 staining was graded as negative,
weak positive, moderate positive, and strong positive (respectively scored as 0–3), and the expression level was compared between normal colorectal epithelium
and CRCs using Wilcoxon signed rank test (p < 0.001). Other representative images are shown in Figure S5, and detailed information can be found in Tables S1
and S2.
(E) qRT-PCR assay showed lower expression level of ArhGAP15 in CRCs than in normal colorectal epithelium cells. Total mRNAwas isolated from 18 pairs of CRC
and normal tissue samples, and the expression level of ArhGAP15 was determined by RT-PCR. Each symbol in the scatterplot indicates the value from one
individual. The difference of ArhGAP15 expression levels was compared between CRC and normal tissue by paired Student’s t test (p < 0.001), and the clinical
information about these samples can be found in Table S5.
See also Figure S5, and Tables S1, S2, and S5 for details.at 21C. Whole-cell lysate was fractionated by BN-PAGE (NativePAGE Sys-
tem; Invitrogen) following the product manual. For BN-PAGE (first dimension),
cell lysate was added with 20% (w/v) glycerol and 5 mM Coomassie G-250
before loading onto 3%–12% Novex Bis-Tris gradient gels. The electropho-
resis was performed in a running buffer containing 50 mM Bis-Tris andC50 mM Tricine (plus 0.004% Coomassie G-250 in cathode buffer) under fixed
voltage (100 V) at 21C for 120 min. Each lane of the BN-PAGE gel was treated
with 5 mMCoomassie G-250 buffer at 42C for 1 min and assembled into one-
lane SDS-PAGE gel (Invitrogen). The SDS-PAGE (second dimension) was per-
formed by 10% Bis-Tris gels in MES-SDS running buffer (0.1% SDS, 50 mMell Reports 3, 1526–1538, May 30, 2013 ª2013 The Authors 1535
Figure 6. Specificity of RhoGAP-p53 Interaction Is Determined by Expression and Localization of RhoGAPs
(A) qRT-PCR showing the mRNA levels of different RhoGAPs in U87 cells before and after irradiation-induced DNA damage. The specific primers for qPCR are
listed in Table S4, and GAPDH was used for normalization. Only a subset of RhoGAPs (including ArhGAP11A, ArhGAP19, and ArhGAP26) was significantly
upregulated in response to DNA damage stress.
(B) ThemRNA level of CDKN1A/p21 (p53 transcriptional target) as detected by qPCR. The U87 cells were treated with siRNAs targeting the indicated RhoGAPs or
scrambled control siRNA, followed by irradiation exposure for inducing DNA damage. All conditions were comparedwith an irradiation-control siRNA group. Data
represent mean values ± SD of four independent experiments (***p < 0.001, *p < 0.05, Student’s t test). Although knockdown of ArhGAP11A significantly
decreased CDKN1A mRNA level, other RhoGAPs did not show a substantial effect.
See also Figure S6, and Tables S3 and S4 for details.MES, and 50 mM Tris-Base). After the 2D BN/SDS-PAGE, proteins were
stained with Coomassie, and interested spots were trypsin digested in the
gel and analyzed by mass spectrometry as described previously (Thebault
et al., 2000).
One-Dimensional BN-PAGE and Western Blot
For details, see the Extended Experimental Procedures.
CoIP
SaOS-2 cells cotransfected with HA-tagged p53/p63/p73 and Flag-tagged
ArhGAP11A were lysed with RIPA buffer with DNase and protease inhibitors
for 30 min at 21C. The cell lysate (300 ml) was incubated with 2 ml monoclonal
antibody for HA tag (Covance) overnight at 4C. Then 30 ml of immobilized pro-
tein G agarose (Thermo Fisher Scientific) was added, which had been blocked
with 2%BSA and untransfected SaOS-2 cell lysate overnight. After incubation
at 21C for 2 hr, the agarose beads were rinsed with 200 ml TBS for five times
and subsequently eluted by heating at 95C in the presence of SDS. The coim-1536 Cell Reports 3, 1526–1538, May 30, 2013 ª2013 The Authorsmunoprecipitated ArhGAP11A was detected with rabbit Flag antibody
(Abcam).
For coIP of endogenously expressed ArhGAP11A and p53, cultured human
or mouse neuron cells were lysed (48 hr after transfection of siRNAs while
applicable) using RIPA buffer with DNase and protease inhibitors for 30 min
at 21C. The cell lysate (300 ml) was incubated with 2 ml Do-1 mouse anti-
p53 (Santa Cruz Biotechnology) overnight at 4C. Then 30 ml of immobilized
protein G agarose was used for precipitation. After western blot, the
ArhGAP11A in the precipitated complex was detected using rabbit polyclonal
antibody for ArhGAP11A (Abcam).
Luciferase Reporter Assay
For details, see the Extended Experimental Procedures.
qRT-PCR
The qRT-PCR assay was performed as described previously by Carr et al.
(2012). Cells were cotransfected with indicated vectors and incubated for
Figure 7. Schematic Representation of the
Interaction between the RhoGAPs and p53
(A) The p53 protein is in equilibrium between
monomeric, dimeric and tetrameric conforma-
tions, and RhoGAP promotes the formation of
tetrameric p53.
(B and C) This promotes the transactivation of p53
target genes p21, GADD45A, BAX, NOXA, etc.,
thereby inducing cell-cycle arrest and apoptosis.
(D) RhoGAPs regulate actin remodeling and cell
morphology through the Rho GTPase pathway,
and by enhancing p53 function, RhoGAPs also
regulate cell proliferation.
(E) These two pathways synergetically mediate the
regulatory effects of RhoGAPs on differentiation
and proliferation.48 hr before isolation of total RNA using RNeasy mini kit (QIAGEN). Reverse
transcription was performed using the iScript cDNA Synthesis Kit (Bio-Rad)
according to the manufacturer’s protocols. PCR was performed using SYBR
Green SuperMix (QIAGEN) on an iCycler iQ Real-Time PCR Detection System
(Bio-Rad), using the specific primers for GAPDH, ACTB, CDKN1A, CCNG1,
GML, BAX, NOXA, PUMA, and all RhoGAPs as listed in Table S4. Gene expres-
sion levels were normalized using either GAPDH or ACTB.
Flow Cytometry
Flow cytometry was performed as described previously by Charalampopoulos
et al. (2012). For details, see the Extended Experimental Procedures.
BrdU Incorporation Assay
To determine DNA synthesis rate, cells were cultured in 4-well slide chambers
in the presence of 10 mM BrdU (Sigma-Aldrich) for 30 min, followed by fixation
with 4% paraformaldehyde and permeabilization using 0.5% Triton X-100 in
PBS. DNA was denatured by treating with 0.07 M NaOH for 3 min and neutral-
ized by rinsing with TBS. After blocking with 1% BSA in TBS, slides were incu-
bated with FITC-labeled anti-BrdU (Santa Cruz Biotechnology) and DAPI.
ChIP Coupled to Quantitative PCR
For details, see the Extended Experimental Procedures.
RhoGAP Activity Assays
The in vitro RhoGAP assay was performed using a GAP assay kit (BK105;
Cytoskeleton) according to the product manual. For details, see the Extended
Experimental Procedures.SUPPLEMENTAL INFORMATION
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